Neurogene Inc. (NGNE) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
the bull case· 2
113
managers reporting a position in institutional regulatory filings
13fJun 30 '26+1.43%
change in shares held by the largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 3
3
funds on file reporting a position in NGNE
n-portas of Jun 30 '2610 of 22
largest reporting managers that reduced their stake in the latest quarter
13fJun 30 '260.01%
iShares Russell ETF's share of its assets as the largest fund weight on file
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 13 '26 report. Not a forecast, not advice.
Of the 6 companies Neurogene Inc. moves with most closely, none share its SEC classification.
Measured against 126 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
NGNE (Neurogene Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
112 managers report a position worth $548.8M between them, and 16 of them hold 80% of it.
Neurogene Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 32.59 at 3:30 pm ET, low 31.63 at 5:45 pm ET.